Jim Cramer on Johnson & Johnson pausing its coronavirus vaccine trial after 'adverse event'

The study of Johnson & Johnson's Covid-19 vaccine has been paused due to an unexplained illness in a study participant. CNBC's Jim Cramer and David Faber discuss the development and whether it affects Johnson & Johnson's stocks.
Tue, Oct 13 20209:58 AM EDT